News & Events - MitoRx

- Press Release
- Posted 9 June, 2026
MitoRx Therapeutics Strengthens Leadership Team with C-Suite and Board Appointments to Support Next Phase of Growth
Read More
- Press Release
- Posted 8 June, 2026
MitoRx Therapeutics presents promising preclinical data on MTRX31, a mitochondrial-targeted small molecule for metabolically unhealthy obesity, at the American Diabetes Association’s 2026 Scientific Sessions
Read More
- Event
Sachs 2nd Annual Obesity and Cardiometabolic Innovation Forum, June 5
Read More
- Event
American Diabetes Association Scientific Sessions 2026, June 5-8
Read More
- Publication
- Posted 1 June, 2026
Myo-004 (MTRX31) induces bodyweight loss in DIO at thermoneutrality by switching metabolism from fat to carbohydrate oxidation
Read More
- Event
European Association for the Study of Diabetes (EASD), 28 September – 2 October
Read More
- Press Release
- Posted 27 May, 2026
MitoRx Therapeutics to present new preclinical data on MTRX31 at the American Diabetes Association’s 2026 Scientific Sessions
Read More
- Press Release
- Posted 17 November, 2025
MitoRx Therapeutics raises GBP 5.5 million pre-series A round to advance a next generation obesity treatment
Read More
- Press Release
- Posted 16 September, 2025
MitoRx Therapeutics presents additional muscle preservation and liver-fat clearance data in obesity at EASD
Read More
- In The Media
- Posted 29 August, 2025
Rethinking Weight Loss Treatments – The Medicine Maker
Read More